Long-Acting Growth Hormone Therapy in Pediatric Growth Hormone Deficiency: A Consensus Statement
An erratum to this article was published (J Clin Endocrinol Metab, 22 Apr 2025 ↗)
Methodological detailsinternational expert consensus, targeted literature search
- International expert consensus
- Targeted literature search
Recommendations
As issued by the authors
Long-acting growth hormone (LAGH) offers a potential advantage over daily growth hormone (GH) injections in children with GHD through reduced injection frequency and treatment burden; this may also be associated with improved adherence and treatment outcomes over time
Data on LAGH in pediatric GHD are mostly limited to clinical trials; long-term, real-world data are lacking
Original publication
Long-Acting Growth Hormone Therapy in Pediatric Growth Hormone Deficiency: A Consensus Statement. J Clin Endocrinol Metab. Published 3 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →